Top

Indian Journal of Hematology and Blood Transfusion

Published in:

10-08-2021 | Original Article

Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry

Authors: R. Gupta, P. Gupta, K. Rahman, S. Biswas, D. Chandra, M. K. Singh, M. K. Sarkar, A. Gupta, S. Nityanand

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2022

Abstract

Flow cytometric (FCM) immunophenotyping is an important tool for generating diagnostic and prognostic information in plasma cell dyscrasias. This study aimed to evaluate the immunophenotype and ploidy status of plasma cells (PCs) in patients of myeloma and its correlation with other laboratory parameters. Bone marrow of 70 newly diagnosed cases of myeloma were subjected to FCM using a panel of antibodies; CD138, CD38, CD19, CD45, CD28, CD81, CD56, CD200, and CD229. FxCycle Violet (FCV) dye was used for the ploidy analysis of clonal PCs. Median age was 60 years with M:F ratio of 3.2:1. A positive correlation was noted between the morphological and FCM-based PC enumeration (r = 0.4, p = 0.001). Aberrant expression of CD56, CD200, CD28, CD117, CD81 and CD19 and was observed in 88.5%, 77%, 29%, 37%, 23% and 17% cases respectively. Two aberrant antigens were noted in all cases. CD81 + cases had a relatively higher quantity of monoclonal-protein (> 1 g/dl, p < 0.05) and renal insufficiency (Cr > 2 mg/dl, p < 0.05) as compared to the CD81- cases. CD229 was expressed in all the cases, with a median MFI in PCs significantly higher than other hematopoietic elements. Hyperdiploid PCs (median DI-1.59, range, 1.16–2.6) were noted in 80% cases (n = 48), diploid/ near-hyperdiploid PCs in 8% (n = 5) cases and hypodiploidy in 3% (n = 1) cases. Bright CD56/CD200 and CD45- can identify abnormal PC in the majority of the cases. CD81 appears to correlate with disease burden and might be useful as a prognostic marker. CD229 is a reliable gating marker for plasma cells. Ploidy analysis may be incorporated in routine workup to guide in the identification of patients with poor prognosis.

Available only for authorised users

Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, Vídriales MB, López-Berges MC, Miguel JF, Orfao A (2010) Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry B Clin Cytom 78(4):239–252. https://doi.org/10.1002/cyto.b.20512CrossRefPubMed

Peceliunas V, Janiulioniene A, Matuzeviciene R, Griskevicius L (2011) Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors. Cytometry B Clin Cytom 80(5):318–323. https://doi.org/10.1002/cyto.b.20601CrossRefPubMed

Robillard N, Wuillème S, Moreau P, Béné MC (2014) Immunophenotype of normal and myelomatous plasma-cell subsets. Front Immunol 31(5):137. https://doi.org/10.3389/fimmu.2014.00137CrossRef

Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A (2016) Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 90(1):61–72CrossRef

Lin P, Owens R, Tricot G, Wilson CS (2004) Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 121(4):482–488. https://doi.org/10.1309/74R4-TB90-BUWH-27JXCrossRefPubMed

Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF (2008) PETHEMA study group; GEM Study Group. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 26(16):2737–2344CrossRef

Guo J, Su J, He Q, Li X, Zhao Y, Gu S, Fei C, Chang C (2016) The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma. Hematology 21(3):152–161. https://doi.org/10.1179/1607845415Y.0000000010CrossRefPubMed

Pojero F, Flores-Montero J, Sanoja L, Pérez JJ, Puig N, Paiva B, Bottcher S, van Dongen JJ, Orfao A (2016) EuroFlow group. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry B Clin Cytom 90(1):91–100CrossRef

Darzynkiewicz Z, Halicka HD, Zhao H (2010) Analysis of cellular DNA content by flow and laser scanning cytometry. Adv Exp Med Biol 676:137–147. https://doi.org/10.1007/978-1-4419-6199-0_9CrossRefPubMedPubMedCentral

10.

Tembhare P, Badrinath Y, Ghogale S et al (2016) A novel and easy FxCycle^TM violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping. Cytometry A 89(3):281–291. https://doi.org/10.1002/cyto.a.22803CrossRefPubMed

11.

Morgan RJ Jr, Gonchoroff NJ, Katzmann JA, Witzig TE, Kyle RA, Greipp PR (1989) Detection of hypodiploidy using multi-parameter flow cytometric analysis: a prognostic indicator in multiple myeloma. Am J Hematol 30(4):195–200. https://doi.org/10.1002/ajh.2830300402CrossRefPubMed

12.

Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, Fonseca R (2013) Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica 98(10):1586–1592. https://doi.org/10.3324/haematol.2012.081083CrossRefPubMedPubMedCentral

13.

Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P (2009) Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol 132(5):728–732. https://doi.org/10.1309/AJCP1GYI7EHQYUYKCrossRefPubMed

14.

Cho YU, Park CJ, Park SJ, Chi HS, Jang S, Park SH, Seo EJ, Yoon DH, Lee JH, Suh C (2013) Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients. J Korean Med Sci 28(4):542–549. https://doi.org/10.3346/jkms.2013.28.4.542CrossRefPubMedPubMedCentral

15.

Shim H, Ha JH, Lee H, Sohn JY, Kim HJ, Eom HS, Kong SY (2014) Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. Biomed Res Int 2014:893243. https://doi.org/10.1155/2014/893243CrossRefPubMedPubMedCentral

16.

Salama ME, Du S, Efimova O et al (2015) Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities. Leuk Lymphoma 56(2):426–433. https://doi.org/10.3109/10428194.2014.931951CrossRefPubMed

17.

Gupta S, Karandikar NJ, Ginader T, Bellizzi AM, Holman CJ (2018) Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters. Cytometry B Clin Cytom 94(3):500–508. https://doi.org/10.1002/cyto.bCrossRefPubMedPubMedCentral

18.

Chen F, Hu Y, Wang X, Fu S, Liu Z, Zhang J (2018) Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis. Cancer Med 7(12):5920–5927. https://doi.org/10.1002/cam4.1840CrossRefPubMedPubMedCentral

19.

Draxler DF, Wutzlhofer LM, Slavka G, Hübl W, Ludwig H, Schreder M, Reynolds J, Willheim M (2019) Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias. Indian J Hematol Blood Transfus 35(4):673–682. https://doi.org/10.1007/s12288-019-01105-wCrossRefPubMedPubMedCentral

20.

Alapat D, Coviello-Malle J, Owens R, Qu P, Barlogie B, Shaughnessy JD, Lorsbach RB (2012) Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol 137(1):93–100. https://doi.org/10.1309/AJCP59UORCYZEVQOCrossRefPubMed

21.

Olteanu H, Harrington AM, Hari P, Kroft SH (2011) CD200 expression in plasma cell myeloma. Br J Haematol 153(3):408–411. https://doi.org/10.1111/j.1365-2141.2010.08555.xCrossRefPubMed

22.

Nair JR, Carlson LM, Koorella C, Rozanski CH, Byrne GE, Bergsagel PL, Shaughnessy JP Jr, Boise LH, Chanan-Khan A, Lee KP (2011) CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol 187(3):1243–1253. https://doi.org/10.4049/jimmunol.1100016CrossRefPubMed

23.

Hundemer M, Klein U, Hose D, Raab MS, Cremer FW, Jauch A, Benner A, Heiss C, Moos M, Ho AD, Goldschmidt H (2007) Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Trans 40(11):1033–1037. https://doi.org/10.1038/sj.bmt.1705857CrossRef

24.

Kraj M, Sokołowska U, Kopeć-Szlezak J, Pogłód R, Kruk B, Woźniak J, Szpila T (2008) Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma 49(2):298–305. https://doi.org/10.1080/10428190701760532CrossRefPubMed

25.

Sahara N, Takeshita A, Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T, Tamashima S, Nara K, Ohnishi K, Ohno R (2002) Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Haematol 117(4):882–885. https://doi.org/10.1046/j.1365-2141.2002.03513.xCrossRefPubMed

26.

Tembhare PR, Ghogale S, Tauro W, Badrinath Y, Deshpande N, Kedia S, Cherian K, Patkar NV, Chatterjee G, Gujral S, Subramanian PG (2018) Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. Cytometry B Clin Cytom 94(3):509–519. https://doi.org/10.1002/cyto.b.21619CrossRefPubMed

27.

Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Kröger N, Luetkens T, Atanackovic D (2015) CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother 11(7):1606–1611. https://doi.org/10.1080/21645515.2015.1046658CrossRefPubMedPubMedCentral

28.

Almeida J, Orfao A, Ocqueteau M, Mateo G, Corral M, Caballero MD, Blade J, Moro MJ, Hernandez J, San Miguel JF (1999) High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 107(1):121–131. https://doi.org/10.1046/j.1365-2141.1999.01685.xCrossRefPubMed

Title: Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry
Authors: R. Gupta
P. Gupta
K. Rahman
S. Biswas
D. Chandra
M. K. Singh
M. K. Sarkar
A. Gupta
S. Nityanand
Publication date: 10-08-2021
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 3/2022
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-021-01477-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Donor’s Perspectives on Blood Donation During Covid-19 Pandemic

Targeted Sequencing Identifies the Genetic Variants Associated with High-altitude Polycythemia in the Tibetan Population

Bullous Sweet Syndrome

Programmed Cell Death Ligand 1 Expression Level and Prognostic Significance in Acute Myeloid Leukemia

Significance of Adopting Nucleic Acid Amplification Technique for Blood Donor Screening in a Resource Limited Setting: A Study from a Single Centre in South India

Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer